CRISPR and RNAi Genetic Screens, Libraries and Construct; Sequencing; RNA Expression Profiling; Barcode Libraries

Cellecta, Inc. specializes in advanced technologies for gene expression profiling and functional analysis, particularly in the context of adaptive immunity and CRISPR-based applications. Their DriverMap™ Adaptive Immune Receptor (AIR) Profiling Assays provide comprehensive and sensitive profiling of T-cell and B-cell receptors (TCR/BCR) from DNA or RNA, enabling researchers to analyze immune responses at a granular level. The DriverMap technology allows for the quantification of gene expression from total RNA without the need for mRNA enrichment, making it a robust option for single-cell analysis. Additionally, Cellecta offers CRISPR and RNAi screening services, which facilitate the identification of new drug targets and biomarkers through loss-of-function and gain-of-function studies.

Furthermore, Cellecta's CloneTracker™ technology provides innovative solutions for cell tracking and single-cell analysis. Their expressed lentiviral barcode libraries enable the labeling of individual cells, allowing researchers to monitor cell lineage and behavior over time. This technology is particularly useful in studying complex biological processes such as differentiation and tumorigenesis. Cellecta also offers a range of lentiviral products and services, including Cas9-expressing cell lines for CRISPR knockout studies and pseudotyped lentiviral particles for coronavirus research, which facilitate the investigation of viral interactions in a safer laboratory environment. Overall, Cellecta's technologies are designed to enhance the understanding of gene function and cellular dynamics in various research applications.

United States

Cellecta provides HT loss-of-function genetic screening services for the discovery and functional characterization of novel therapeutic targets.  We offer pooled lentiviral shRNA and CRISPR libraries, pooled library screening and analysis by NGS, targeted RNA-Seq for biomarker discovery, lentiviral reagents, and stable cDNA, shRNA, and CRISPR constructs and isogenic cell lines.

Cellecta, Inc.

Company Details